Behçet's disease (BD) is a systemic disorder characterized by recurrent oral aphthous ulcers, genital ulcers, uveitis and skin lesions (O'Duffy 1990; Sakane et al. 1999; Yurdakul et al. 2004) . Vascular involvement is a major clinical feature of BD. The incidence of vascular involvement has been reported between 7.7% and 43% in patients with BD Ames et al. 2001; Yurdakul et al. 2004) . Although venous thrombosis is a common clinical manifestation, the causes of venous thrombosis are still unknown in patients with BD (Kiraz et al. 2002; Yurdakul et al. 2004 ). However, the endothelial dysfunction is thought to play a key role for development of thrombosis in BD (Schmitz-Huebner and Knop 1984; Koşar et al. 2002; Ozdemir et al. 2004) . Additionally, there is the hypercoagulable/prothrombotic state in BD, which is also important in development of thrombosis (Gül et al. 2001; Kiraz et al. 2002; Koşar et al. 2002) . Although the coagulation system, fibrinolytic activity and thrombophilic factors were studied extensively in patients with BD, platelet function, which is a major component of hemostasis and thrombosis, has not been evaluated sufficiently.
Mean platelet volume (MPV) reflects platelet function and activity (Martin et al. 1991; Smith et al. 1999; Park et al. 2002) . Changes in platelet behavior, such as increased platelet aggregability, have been proved to be an independent risk factor for cardiovascular events (Martin et al. 1991; Park et al. 2002) . Platelet production and stimulation indirectly elevates values, which can result in cardiovascular disease, as larger platelets are more reactive than normalsized ones (Park et al. 2002; Chu et al. 2010) . Taking into account the thrombotic complication in BD patiens, we hypothesized that there might be an association between thrombotic complication and MPV in these patients. Therefore, we compared MPV in BD patients with that of healthy controls. We also analyzed the defference in MPV between BD patients with and without thrombosis and between patients with active and inactive disease states.
Materials and Methods

Study group
A total of 60 patients with BD fulfilling the inclusion criteria (29 female and 31 male, mean 40.5 ± 12.9 years) and 40 controls (22 female and 18 male, mean 41.3 ± 6.8, years) were included to the study. The diagnosis of BD was made according to the criteria of International Study Group. The control group consisted of sex-and age-matched healthy subjects. A detailed history was taken and each participant underwent a systemic physical examination to exclude cardiovascular or other relevant disease before attending to the study. The exclusion criteria were hematological disorder, impaired coagulation tests, hyperlipidemia, hypertension, smoking, diabetes mellitus, renal and hepatic failure, antiphospholipid antibody positivity, active infectious disease, malignancy immunological disease and chronic obstructive lung disease. None of the patients took oral anticoagulant drugs, aspirin and other antiplatelets drugs during the blood sampling. The 20 of the patients with BD were taking colchicine but not the other drugs. However, it was stopped at least 3 days before the blood sampling.
The BD patients were divided to subgroups based on the presence (n = 22) or absence of thrombosis (n = 38) and these patients were also classified as active (n = 30) or inactive (n = 30) state according to clinical findings depending on the presence of at least two of the following criteria: oral ulcers, genital ulceration, eye lesions, skin lesions, arthritis and thrombophlebitis. The diagnosis of vascular thrombosis was confirmed by clinical findings, Doppler ultrasonography and/or angiography. In additon to MPV, some hematological paramaters such as erythrocyte sedimentation rate (ESR), total platelet count, white blood cell count and C-reactive protein (CRP) were measured in all subjects. The study protocol was approved by the institutional ethics committee and all participants gave informed consent.
Laboratory analysis
All blood samples were drawn from the antecubital vein at 08.00-10.00 a.m. after a fasting period of 12 hours. Analyses were performed immediately after sampling to prevent in vitro platelet activation. MPV and the other hematological parmaters were measured by using Beckman Coulter LH 780 Hematology Analyzer. The expected values for MPV in our hematology laboratory ranged from 6.8 to 10.8 fl. Serum CRP levels were measured by nephelometric method (Behring Nephelometer Analyzer, Germany) and ESR was also measured by Westergren method. The reference ranges for CRP and ESR are 0 to 3.13 mg/l, and 1 to 20 mm/h, respectively.
Statistical analysis
Statistical analysis was performed by using the SPSS for windows 11.0 (Chicago, Illinois, USA). Data were expressed as mean ± 
Results
There was no significant difference between BD and controls in terms of baseline demographic properties. Among 22 BD patients with vascular thrombosis, 17 were male patients, and the distribution of thrombi was in vena cava superior (n = 1), vena cava inferior (n = 3) and deep vein thrombosis (n = 18), repectively. Baseline demographic properites of BD patients are shown in Table 1 . MPV was higher in patients with BD than that in controls (8.14 ± 0.8 vs. 7.48 ± 0.3 fl, p = 0.001, respectively) ( Table 2 ). The other laboratory paramaters are also listed in Table 2 .
Among BD patients, MPV was higher in patients with thrombosis than the value in those without thrombosis (8.45 ± 1.0 vs. 7.96 ± 0.7 fl, p = 0.038, respectively) ( Table 3 ). In contrast, there was no significant difference in MPV between BD patients with active state and those with inactive state (8.20 ± 0.6 vs. 8.08 ± 1.0 fl, p = 0.6, respectively) ( Table 4) . Correlation analysis showed no significant association between MPV and any other parameter.
Discussion
Principle findings of this study were 1) MPV was significantly higher in patients with BD when compared with that of controls, 2) MPV was higher in BD patients with thrombosis than those without thrombosis, and 3) there was no significant difference in MPV between BD patients in active and inactive state. To our knowledge, this is the first study showing the increased MPV in patiens with BD.
BD is a multisystemic vasculitis with obscure etiology. Thrombotic complications have been reported in approximately 12-40% of patients with BD . Venous thrombosis, especially deep vein thrombosis of lower extremity, is the common clinical manifestation in vascular BD (O'Duffy 1990; . Venous thrombosis in BD is mainly observed in males (O'Duffy 1990; Kiraz et al. 2002; Duzgun et al. 2006 ). In our study, the characteristics of BD patients with venous thrombosis were similar to previous studies. The exact pathogenic mechanism underlying the venous thrombosis is still unclear. However, vascular endothelial cell injury and resultant endothelial dysfunction are thought to play a central role in the development of thrombosis (Schmitz-Huebner and Knop 1984; Kiraz et al. 2002; Koşar et al. 2002; Ozdemir et al. 2004; Duzgun et al. 2006) . Investigations of the hemostatic parameters have shown activation of both coagulation and fibrinolytic systems suggesting endothelial activation or injury. Kiraz et al. (2002) reported that procoagulant markers of thrombosis reflecting intravenous excessive thrombin formation, defective fibrinolyis and hypercoagulable/prothrombotic state and endothelial injury were associated thrombotic complication in BD. Akar et al. (2006) evaluated circulating activated platelets and platelet reactivity in BD and demonstrated that platelets in BD patients were active and more reactive than normal controls and concluded that this might contribute to the thrombotic tendency. Yapişlar et al. (2007) suggested decreased nitric oxide and increased platelet aggregation in patients with BD, particularly in the inactive period and concluded that the risk of thrombosis was independent of the disease activity phase. In according with these reports we found that MPV values were increased in BD patients particularly with thrombosis independent of the disease activity.
Platelets play an important role in the process of hemostasis and thrombosis. Following injuries to blood vessels and in certain pathologic conditions, platelets adhere to the exposed subendothelial connective tissue, aggregate and release several biologically active substances (Chiang et al. 2002). Alteration in platelet aggregation is the main event leading to imbalance in hemostasis, which may eventually lead to thrombotic disorders. In addition, platelet aggregation may contribute to the vasculitis occurring in BD (Singh et al. 2002) . Accordingly, MPV is a marker of platelet function and large platelets contain more dense granules and produce more thromboxane A2 (Kamath et al. 2001; Park et al. 2002) . Increased MPV has been associated with greater in vitro aggregation in response to ADP and collagen (Kamath et al. 2001) . Increased platelet size has been reported in patients with vascular risk factors such as diabetes, smoking and acute ischemic stroke (Tschoepe et al. 1991; Kario et al. 1992; Smith et al. 1999) . Therefore, increased MPV could be regarded as a marker for development of thrombosis in BD. There is no optimal aprooach for the treatment of venous thrombosis in BD. The treatment modalities include immunosuppressives agents such as azathioprine, aspirin and anticoagulation for deep vein thrombosis. However, the use of anticoagulants or anti-platelet agents in the management of thrombosis in BD is controversial. The venous thrombi in BD adhere to the vessel wall but do not result in emboli, and pulmonary embolism is rare despite a high frequency of venous thrombosis and thus anticoagulants are not recommended (Hatemi et al. 2008) . Ahn et al. (2008) reported that immunosuppressive therapy, rather than anticoagulation therapy, is essential for the treatment of deep venous thrombosis associated with BD. Regarding the use of aspirin, while some have recommended the others does not (Sakane et al. 1999; Yazıcı et al. 2007; Yapişlar et al. 2007; Hatemi et al. 2008) . From the clinical point of view, only depending on increased MPV values, it is difficult to claim that anti-platelet and anticoagulant agents should be given to all BD patients. However, at least it should be kept in mind that together with defective fibrinolyis, hypercoagulable/ prothrombotic state and endothelial injury, increased MPV values may be one of the paramaters facilitating thromboembolic complication in these patients
Study limitations
The main limitation of our study was lack of the other markers of platelet activation and aggregation such as platelet factor 4 and beta thromboglobulin, thrombotic status (fibrinopeptide A and thrombin-antithrombin III complex) and fibrinolytic status (D-dimer and plasmin-alpha 2-plasmin inhibitor complex). The other limitation was the fact that only small number of patients were included.
Conclusion
Patients with BD have higher MPV, indicating the tendency toward platelet aggregation, when compared to controls, and the presence of thrombosis is associated with higher MPV in these patients. However, further large-scale studies are required to clarify whether the BD patients with high MPV are at greater risk for thrombotic complications and may benefit from the anti-platelet therapy.
